All News
DSB: Drug Shortages - October 2015
Each month, RheumNow reviews compiled listings of drug shortages germane to the practive of rheumatology using several sources. If you have suggestions or information about specific drug shortages or drug safety issues please email us at info@rheumnow.
Read Article
Sleep Apnea Increases Risk of Gout
Zhang and colleagues from Boston analyzed patients with physician diagnosed sleep apnea from The Health Improvement Network in the UK and compared these with 5 controls (age, sex, BMI matched). They studied 9,865 patients with sleep apnea and 43,598 controls.
Read Article
Initiation of Urate-Lowering Therapy During Gout Attacks
A retrospective analysis examined whether it's better to initiate urate-lowering therapy (ULT) during or after an attack of acute gout.
Read Article
Toxoplasma Infections in the Immunosuppressed
In the USA, toxoplasmosis is the second leading cause of foodborne illness–related death and hospitalization, with >300 deaths and 4000 hospitalizations each year [2]; 4800 people develop visual loss yearly secondary to the parasite.
Read Article
FDA Holds Off on Xeljanz Approval for Psoriasis
The FDA has denied Pfizer's application seeking an indication for Xeljanz in patients with moderate to severe chronic plaque psoriasis.
Read Article
Dietary Supplements Send 23,000 to the ER Annually
The CDC has reported in the NEJM that dietary supplements may be associated with higher than expected rates of adverse events requiring medical evaluation in the emergency department (ED).
Read Article
Hydroxychloroquine Retinal Toxicity Reviewed
Hydroxychloroquine (HCQ or Plaquenil) retinopathy is rare, but still a major concern among patients and prescribers.
Read Article
DSB Reports and Updates - October 2015
This month's DSB addresses labeling changes as well as safety reports from literature, including steps to prevent major birth defects, timing and intervals between PCV13 and PPSV23 vaccines, PPIs and subacute cutaneous lupus, and FDA warnings on tramadol in children.
Read Article
Infertility in Rheumatoid Arthritis Linked to Disease Activity
Women with rheumatoid arthritis are said to have a normal number of pregnancies. However, most of these are conceived prior to the onset of RA. Once diagnosed, the RA patient who wishes to become pregnant may be faced with difficult medication choices if she is planning to become pregnant.
Read Article
Increased Risk of Shingles with Inflammatory Myositis
A study from the Taiwan National Health Insurance examined 2023 patients with new diagnoses of dermatomyositis or polymyositis and population controls and examined the frequency of Herpes zoster.
Read Article
Secukinumab Wins in Psoriatic Arthritis
Mease and colleagues have published their results of a phase 3 trial of secukinumab (anti-IL-17A Mab) in 606 patients with psoriatic arthritis (PsA).
Read Article
DSB: Drug Shortages - September 2015
RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins. Each month we will update you with reports of new, ongoing and resolved Drug Shortages that will affect the practicing rheumatologist.
Read Article
High Sodium Intake Linked to Risk of RA
Diet has long been considered a potential risk factor for the onset or pathogenesis of rheumatoid arthris. Obesity and the microbiome are being intensively studied as risk factors for RA.
Read Article
The Deadly Truth behind Paxil’s Study 329
Study 329 was published in 2001, and became a pivotal study for the anti-depressant drug Paxil (paroxetine). In 2002, over 2 million prescriptions were written for Paxil.
Read Article
PLLR - The Pregnancy & Lactation Labeling Rule Explained
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Read Article
DATA-Switch Study Finds the Right Sequence to Building Better Bone Mass
Long-term management of osteoporosis can be challenging, and given the increasing number of choices, the best sequence of drug use has not been addressed adequately.
Read Article
Monitoring of Novel Therapies in Rheumatology
The rheumatology therapeutic landscape has changed almost yearly in the last 15 years, with the introduction of at least 16 biologic or novel agents for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA), juvenile arthritis,
Read Article
Shingles Vaccine Not Cost-Effective in Those Under 60
The herpes zoster (HZ- shingles) vaccine was FDA approved for use in individuals over age 50 years. However, the CDC Advisory Committee on Immunization Practices (ACIP) has recommended it only be used in those over age 60 years.
Read Article
Drug Safety Reports & FDA Updates – August 2015
Safety reports from literature include long-term safety of rituximab, rituximab-induced neutropenia, tabalumab (Anti-BAFF Mab) results from the ILLUMINATE trial, colchicine toxicity increased in CKD patients, FDA updates and drug labeling changes, and more.
Read Article
Serious Infections Increased in Etanercept-Treated Juvenile Arthritis Patients
UK researchers set out to study medically significant infections (MSI) in juvenile idiopathic arthritis patients enrolled in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).
Read Article
